Home › Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes
 

Keywords :   


Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes

2013-03-28 09:57:29| dairynetwork News Articles

Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes. The trial will evaluate the use of BIOD-123 versus Humalog® on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.

Tags: the of treatment trial

Category:Agriculture and Forestry

Latest from this category

All news
15.05Exploring the future of agriculture
15.05American, Mexican, and Canadian cattle producers sign joint statement
15.05AgSpire partners with South Dakota State University & others to advance resilience on cattle ranches
15.05TSCRA Disaster Relief Fund distributes $900,000 in financial assistance
15.05Cost of bulls in a stocker program during receiving period explored
15.05Marbling is a beef industry success story
15.05Pork has its place in healthy, sustainable global diets
15.05Iowa food pantries benefit from Pork in the Pantry donations
Agriculture and Forestry »
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
16.05Firms leaving UK 'not a crisis' says stock market boss
15.05Exploring the future of agriculture
15.05American, Mexican, and Canadian cattle producers sign joint statement
15.05Attitudes EWG Verified Skincare Line Oceanly Expands with SPF Offerings
15.05Sherwin-Williams Packaging Coatings Expands Non-BPA Coatings Production in Europe
More »